DermaSensor

America’s first FDA-cleared, AI-powered skin cancer detection device. Clinically proven and trusted by Primary Care Physicians.

DermaSensor is designing an affordable handheld sensor that will be able to evaluate skin for potential cancer in seconds. Results will be displayed instantly. Our device will use machine learning algorithms, a type of artificial intelligence, to more accurately assess potential skin cancer.

12/10/2025

Skin cancer affects 1 in 5 Americans — and early detection saves lives.

When melanoma is found early, survival rates exceed 99%.

DermaSensor gives primary care teams a fast, non-invasive way to assess suspicious skin lesions right in the exam room — with objective results in seconds.

✨ Clinical Highlights:
• 96% sensitivity in a large, multi-center study
• Helped reduce missed skin cancers by half
• Consistent performance across all skin tones

Empowering clinicians with better tools means more patients get the early answers they need.

👉 Explore the clinical evidence behind DermaSensor: https://www.dermasensor.com/resources/filter/content/brochures-clinical-evidence/

12/05/2025

FDA-Cleared AI Skin Cancer Detection for Primary Care — 90 Days Risk-Free

Join primary care practices nationwide detecting skin cancer with 96% sensitivity.

DermaSensor delivers confident diagnoses with:

- Handheld, point-and-click application
- Non-invasive optical spectroscopy
- Cellular-level analysis beneath the skin

Year-End Special:
✓ 90-Day Risk-Free Trial
✓ $0 Setup or Hardware Fees
✓ Free Billing & Reimbursement Guidance

Start 2026 with more confident, AI-supported skin cancer detection at the point of care.

👉 Request a Demo: https://www.dermasensor.com/requestdemo/

For healthcare professionals only.

12/03/2025

We’re honored to announce that DermaSensor has been selected by Inc. Magazine for the 2025 Awards in the Best in Innovation category.

This recognition celebrates companies making a meaningful impact through innovation, ex*****on, and industry leadership — from product breakthroughs to measurable outcomes for customers and communities. Being selected alongside forward-thinking companies such as NVIDIA, AlphaSense, Logitech, Alafair Biosciences, Anthropic, and others, inspires us to keep pushing the boundaries of what’s possible.

At DermaSensor, our team remains focused on advancing early detection of skin cancer in primary care, and this honor highlights the integrity, vision, and ex*****on that drive our mission forward.

Thank you, Inc. Magazine., for this recognition — and congratulations to all fellow honorees shaping the future of business.

12/02/2025

Boston University recently spotlighted the early photonics research that helped shape the technology behind the DermaSensor device.

In the video, Professor Irving Bigio shares how this light-based innovation began in the lab and is now supporting skin-lesion assessments in primary care.

Curious how this technology is being used today?
Learn more or book a demo: https://hubs.li/Q03WwzYC0

11/24/2025

The landscape of AI in healthcare is evolving rapidly; however, many tools are still reaching patients without clinical trials or FDA oversight. A recent article from the Duke University School of Medicine, titled “Current Landscape of AI Regulation in Dermatology,” published in JAAD last week, underscores the necessity of strong regulatory standards.

DermaSensor is one of the few AI dermatology technologies that has received FDA De Novo authorization, supported by a clinical trial involving over 1,000 patients, which demonstrated 96% sensitivity. Importantly, DermaSensor’s algorithm is a locked model, meaning that the version cleared by the FDA is precisely what primary care physicians utilize in their practice.

We agree with the article's viewpoint: both initial authorizations and any future updates to the algorithm must undergo appropriate FDA review to ensure patient safety and promote responsible AI innovation in healthcare.

👉 Read the full article here: https://hubs.li/Q03Vtp2M0

11/12/2025

Technology is transforming how primary care physicians evaluate skin cancer risk. 💡

Dr. Bret Kueber shares how DermaSensor allows him to quickly assess suspicious lesions during routine exams — with no disruption to workflow and immediate results that patients appreciate.

Simple. Non-invasive. Backed by AI.

👇 Watch Dr. Kueber’s experience and hear why he recommends DermaSensor.

11/05/2025

Two newly published studies in JAAD International and JCAD validate the consistent performance of DermaSensor’s FDA cleared, AI-powered device and its ability to improve physicians’ melanoma detection. The studies found:

- Melanoma detection increased from 70.2% to 79.1%, decreasing missed melanoma from 29.8% to 20.9%.
- 91.5% of the study physicians agreed the device added value to their clinical care.
- 75% agreed it would help detect more skin cancers.
- 71% reported increased confidence in evaluating skin lesions.

Now in use by hundreds of physicians, DermaSensor continues to empower clinicians with rapid, objective lesion assessments — helping bridge gaps in dermatology access and improve patient outcomes.

📄 Read the full press release: https://hubs.li/Q03RVxQj0

10/29/2025

Every year, millions of Americans are diagnosed with skin cancer - but most cases can be prevented or treated when caught early.

DermaSensor helps physicians non-invasively assess suspicious skin lesions during routine visits, so patients get the reassurance or next steps they need right away.

💙 Find a DermaSensor provider near you: https://hubs.li/Q03QQt_d0

10/23/2025

🏆 DermaSensor has been named “Best in Class – Clinical Diagnostic Device” at the 2025 Digital Health Hub Awards at ! This recognition celebrates real-world innovation in healthcare and we’re proud to empower primary care with real-time, non-invasive skin cancer detection.

From AI-driven breakthroughs to digital health pioneers, we’re honored to stand alongside inspiring leaders shaping the future of care.

10/17/2025

Evaluating suspicious skin lesions remains a challenge — visual exams are subjective, and dermatology training varies widely among clinicians.

DermaSensor is addressing this challenge with its FDA-cleared, AI-powered spectroscopy device that provides fast, objective insights to assess skin cancer risk and support clinical decision-making in real time.

👉 Learn how DermaSensor is advising skin cancer detection https://hubs.li/Q03P5M9f0

10/10/2025

What a great week FMX2025! 🙌

The excitement and positive feedback we received were incredible. It’s clear that DermaSensor is helping primary care providers bring skin cancer detection directly into their offices.

A special thank you to Dr. Nate Falk, MD, MBA, CPE, FAAFP, for joining our team and sharing his first-hand experience using DermaSensor in practice - and to all the attendees who stopped by and made this such a great event.

Until next year, FMX! 👋

To learn more about our technology and reimbursement options, visit: https://hubs.li/Q03N8QZh0

10/09/2025

This week, our CEO, Cody Simmons, joined medtech leaders at AdvaMed’s MedTech Conference in San Diego to share insights on innovation and how new technologies reach patients faster.

This year’s event marked AdvaMed’s 50th anniversary, uniting thousands of attendees and companies from around the world to explore how medtech continues to shape the future of healthcare.

We appreciate the opportunity to be part of these conversations that foster collaboration and drive innovation across the industry.

👉 Learn more about our technology at https://hubs.li/Q03MZHxS0

Address

Miami, FL
33130

Telephone

+18553736767

Website

https://www.dermasensor.com/

Alerts

Be the first to know and let us send you an email when DermaSensor posts news and promotions. Your email address will not be used for any other purpose, and you can unsubscribe at any time.

Contact The Practice

Send a message to DermaSensor:

Shortcuts

Want your practice to be the top-listed Clinic in Miami?